Phaseline

Companies › Shanghai Best-Link Bioscience

Shanghai Best-Link Bioscience: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BL0175
Estrogen receptor downregulator delivered via nano-medicine formulation
ESR1Phase 2Breast Cancer (Locally Advanced or Metastatic); Breast CancerOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07658183BL0175Phase 2Breast Cancer (Locally Advanced or Metastatic)OncologyOct 2027
NCT06738966BL0175Phase 1Breast CancerOncologyDec 2027

Targets

ESR1 (1)

Companies with the same targets

Pfizer AstraZeneca Roche Eurofarma Laboratorios Eli Lilly Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Stemline Therapeutics Atossa Therapeutics GE Healthcare Novartis

Companies built like this

Atossa Therapeutics LeonaBio Olema Pharmaceuticals Shanghai Guangsheng Biopharmaceutical VIVUS

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.